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Abstract  
Objectives: With IMRT and advanced radiation planning, anatomy and contouring is becoming increasingly 
important in the field of radiation oncology. The use of iodinated computed tomography (CT) contrast for 
radiation simulation CT scans can help define anatomy more precisely and thus improve contouring.  The 
major risks of CT contrast (which at least partly accounts for the aversion by some departments to its routine 
use) are contrast induced nephropathy and allergic-like reactions.  
Results: The evidence of complications attributable to standard doses of contrast for diagnostic CT 
examinations is weak.  The preponderance of data on contrast induced nephropathy has been compiled 
from interventional cardiology procedures, and the current guidelines regarding diagnostic CT contrast 
require extrapolation on mostly retrospective data.  The evidence available suggests that CT contrast 
related adverse events are rare, and contrast related nephropathy most often spontaneously resolves without 
further decline in baseline renal function. 
Conclusion: The current data regarding safety of CT contrast provides a limited foundation on which to 
make evidence-based recommendations. We have reviewed the literature on CT contrast. By following some 
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Introduction 
CT based treatment planning is becoming today’s standard in radiation oncology. An understanding of cross-sectional 
anatomy has becoming increasingly important for the radiation oncologist. With the shift from 2D to 3D treatment 
planning, radiation oncologists have to conceptualize anatomy in multiple planes, and this is even more vital with 
IMRT.  
Anatomy and contouring are one of the most vital and important processes in radiation oncology today. Improved 
quality of the CT images used for simulation results in greater tumor conspicuity, and instills a greater confidence in 
the contouring process. One common method to maximize the quality of a simulation CT scan is to administer 
contrast, especially intravenously (IV) administered contrast. CT contrast can effectively delineate vessels and often 
increases tumor discrimination from normal tissue because of differential tissue enhancement. In this way contouring 
becomes optimal, which in theory translates to better outcomes.  
However, radiation oncology departments are generally much less experienced with IV contrast than are diagnostic 
radiology departments. A consequence of this is that departments may be disinclined to use contrast merely because 
they lack the experience in its delivery. A report on IV contrast usage in UK radiation oncology departments reported 
suboptimal IV contrast use [1].The objective of this review is to outline common indications within radiation 
oncology for which CT images can be substantially improved by the use of CT contrast, to propose a few simple 
algorithms for different body sites, to summarize the potential toxicities of CT contrast, and offer guidelines for how to 
improve safety in administering CT contrast.  
 
Figure 1 axial CT scan without and with contrast. This is an example of how IV contrast (right) can make visualization of the 
hilar lymph node much easier and more accurate than the scan without contrast (left).  
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Table 1 Recommendations for when to use IV contrast 
Treatment 
Site 
Use Contrast for CT 
simulation? 
Note 
CNS No Most times will have MRI that can be used for fusion. In cases where MRI cannot be performed, 




Breast No  
GI Yes  
Thoracic Yes IV contrast should be used to determine mediastinal and hilar lymph nodes. In patients in whom 
there is no lymph node disease or elective nodal treatments IV contrast can be held. 
 
Prostate Variable Can help define vessels but not necessary 
Gyn Variable  Can help define vessels but not necessary  
Soft tissue Variable   
 
Role of IV contrast 
Contrast for CT comes in several forms and may be administered by a variety of routes. For the purpose of this review, 
only iodinated contrast for intravascular administration will be discussed. Briefly, the photons emitted by the fan beam 
of the CT scanner are attenuated by the iodinated contrast media within the patient from reaching the detector opposite 
the fan beam, and the degree to which the beam is attenuated is measured in Hounsfield units. CT contrast is almost 
always injected into the venous system, and depending on the timing of scan acquisition it can help enhance vessels to 
a greater degree than other non-vascular anatomical structures (Figure 1). A second major advantage to contrast is that 
many tumors will either hypo- or hyperenhance with CT contrast relative to surrounding structures, allowing clearer 
distinction of tumor margins.  This is especially crucial in tumors which do not have an exophytic component.  
However, not all body sites require or derive benefit from administration of CT contrast as outline in Table 1.  
CNS 
Most patients with CNS tumors (e.g. glioblastoma multiforme) will have previously undergone an MRI examination. 
While MRI for brain tumor is usually acquired with a gadolinium-based contrast agent, as most CNS tumors are 
contrast-enhancing, MRI is not typically done in the radiation oncology department. Assuming that a high-quality 
MRI examination is available for fusion with simulation CT scan, there is little benefit to performing the CT scan with 
contrast. In the event that an MRI with contrast cannot be performed (e.g. implanted cardiac pacemaker which is a 
contraindication to MRI), the simulation CT scan should be performed with IV contrast.  
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Head and Neck 
Nowhere in the body is the use of contrast more crucial. The multiplicity of vessels, muscles, salivary glands, and 
lymph nodes, their relative small size, and the paucity of space between them poses a challenge to the radiation 
oncologist.  Elective nodal radiation is a critical aspect to head and neck cancer treatments, and IV contrast will help 
delineate lymph nodes, adding precision to contouring. In addition to this, abnormal lymph nodes may enhance 
differently than normal lymph nodes, and the primary tumor itself will often enhance and this will also aid in optimal 
contouring.  
Thoracic 
For patients with lymph node involvement (mediastinal or hilar), IV contrast is vital in being able to distinguish hilar 
vessels from lymph nodes. In patients for whom there is no planned radiation to lymph node regions (early stage 
NSCLC for example) IV contrast can be withheld.  
Gastrointestinal Tract 
IV contrast is very helpful in defining vessels as landmarks for contouring. Both in nonoperative and post-operative 
pancreatic cancer patients it is important to accurately contour portal vein, celiac axis, and superior mesenteric artery. 
These anatomical relationships may be significantly altered in the postoperative patient. 
Adverse effects of IV contrast 
There are two general categories of adverse reactions to iodinated contrast for CT: chemotoxic (contrast induced 
nephropathy), and acute idiosyncratic systemic (also referred to as anaphylactoid and allergic-like). Contrast allergy, 
most often mild, can potentially result in life-threatening anaphylaxis, circulatory collapse, and death. These events are 
rare but have been estimated to occur in 1 case per 200,000 administrations of contrast [2-5]. Contrast-medium 
induced nephropathy (CIN) is a condition in which renal function acutely declines following contrast exposure, with 
no other attributable etiology than the IV contrast.  
Incidence of CIN 
CIN is the third leading cause of acute renal failure in hospitalized patients and can be associated with prolonged 
hospitalization and even death [6,7]. CIN is thought to be caused by direct tubular toxicity and also by renal ischemia 
[8,9]. Interestingly, there is no consensus on the definition of CIN. Most clinical studies [10-12] have used a definition 
of 25% increase in serum creatinine or absolute increase of 0.5 mg within 2 to 7 days of the procedure. The lack of a 
consensus definition for CIN is one of the factors that leads to difficulties in estimating the true incidence of CIN. 
Most of the data regarding incidence of CIN is derived from retrospective studies looking at IV contrast for cardiac 
procedures where there is an overall incidence between 1.6 to 2.3% [13] .This likely leads to an overestimation of CIN 
in non-cardiac diagnostic scans, and there are certainly pitfalls in extrapolation. Intraarterial contrast administration 
(such as that used in cardiac procedures) is thought to pose a greater risk of CIN than intravenous administration [14]. 
Some authors have postulated that IV contrast in diagnostic radiology may not cause CIN at all; a large retrospective 
study looked at 53,439 patients and 157,140 diagnostic CT scans and did not find any difference in CIN rate between 
patients receiving contrast versus those without contrast [15], leading the authors to question if CIN was causal or 
simply coincident.  
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Certain patient subsets undergoing coronary angiography are at a higher risk of CIN, but it should once again be noted 
that these risk factors may not be relevant for non-cardiac patients. Further complicating this is that studies deriving 
risk factors are heterogeneous, retrospective, and often not validated.  Several of the proposed risk factors include 
diabetes [16,17], age [18,19], chronic kidney disease (including multiple myeloma) [17,18,20], use of metformin 
containing medications [21], and hypertension [22,23]. Different studies have determined different risk factors and 
when consensus guidelines rely upon the disparate data, they too lose uniformity. This can be highlighted by using the 
example of metformin containing medications. There is limited evidence linking metformin to CIN in patients taking 
metformin. While often cited as a risk factor for CIN, the data for this is primarily from case reviews and case series 
[21], and there is no evidence that CIN occurs in patients with otherwise normal renal function and there is no 
evidence that withholding metformin prevents CIN [24]. Given the limited quality data regarding CIN risk factors it 
should not be a surprise that there is not uniformity among contrast guidelines.  
Screening for at Risk Patients for CIN 
The major concern with CIN is that the resulting decreased renal function will not be sufficient to support fluid and 
toxin elimination which is the primary role of the kidneys. Patients with already low renal function are the subset at 
greatest risk from CIN. Thus, the most important information to know prior to IV contrast is pre-contrast renal 
function. The single most important quantitative marker for renal function is the glomerular filtration rate (GFR) 
which is the rate at which the kidneys are able to filter volume, and therefore the higher number the better.  GFR is 
approximated by the estimated glomerular filtration rate (eGFR) which can be calculated via the Cockcroft-Gault or 
similar equations [16].  Medical laboratory reports will routinely list the eGFR. For patients with an eGFR greater 
than 60 ml/min the renal function is fully adequate and IV contrast can be safely given. 
As discussed above, there are several proposed risk factors for CIN (Table 2). Especially in the oncology setting, it is 
important to recognize that many chemotherapy agents can be nephrotoxic, and patients receiving such chemotherapy 
should always have close follow-up of their renal function while on chemotherapy [25] (of course most often the 
medical oncologist will be ordering and tracking serum creatinine for these patients). Not all patients need a serum 
creatinine prior to proceeding with IV contrast; young and otherwise healthy patients are at low enough risk for CIN 
that creatinine screening is not indicated [26-27]. In a large study of 2034 outpatients for whom contrast-enhanced CT 
scans were ordered, serum creatinine was checked in all patients, and 66 patients had serum creatinine greater than 2.0 
and 64 of these patients had some risk factor that would have prompted screening. Thus, only 2 of 2034 patients 
(0.1%) would have been missed with selective creatinine screening. While serum creatinine should always be looked 
for if available, for young patients (< 60 years) without risk factors (Table 2) contrast can be given without obtaining 
serum creatinine [28]. For patients who have any of the risk factors in Table 2 a serum creatinine should be obtained 
within 7 days of contrast administration. A simple algorithm (Figure 1) outlines the screening process. 
Table 2 Proposed risk factors for CIN 
Age greater than 60 
Hypertension  
Chronic kidney disease  
Diabetes  
Recent nephrotoxic chemotherapy  
When to require serum creatinine prior to CT scan 
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Contrast Administration in Patients with Elevated Creatinine 
Patients with a low eGFR are at increased risk of CIN. However, it is unclear what the low-limit cutoff should be. 
While nearly all consensus guidelines are in agreement that eGFR > 60 is safe, there is a paucity of data regarding 
CIN in patients with lower eGFR rates, specifically those with rates of 45 to 60. While some authors have 
retrospectively found that eGFR < 60 to be a risk factor for patients undergoing percutaneous coronary intervention 
[16] others have not.  In a study of 1826 consecutive coronary intervention patients there was no case of CIN 
requiring dialysis in patients with eGFR greater than 47. Based on the predictive model, the estimates for CIN 
requiring dialysis with a eGFR of 50 is 0.2% for diabetics and 0.04% for non-diabetics and with a eGFR of 40 is 2% 
for diabetics and 0.3% for non-diabetics. This rate thereafter starts to significantly increase with a rate of 84% for 
diabetic patients with an eGFR of 10 [20]. Thus, while a cut-off of 60 is commonly cited, there is no data to clearly 
support this. Because CIN rates do increase with lower eGFR it stands to reason that caution is used for patients with 
eGFR between 45 and 60 and that consultation with nephrology is used for patients with an eGFR below 45.  
Concerns of CIN should not dissuade use of IV contrast if it is believed that better anatomy visualization would 
improve the treatment planning.  Even when CIN does occur it is almost always transient. Typically serum creatinine 
increases 48 to 72 hours, peaks at 3 to 5 days, and returns to baseline in another 5 to 9 days [29-30].  Short of CIN to 
the extent that dialysis is required, it is unclear if there is any long-term health consequences for transient CIN. While 
several reports have noted overall worse outcomes for patients who had CIN [31-33] it is impossible to determine if it 
was actually the CIN that drives this poor long term survival or if patients with renal function susceptible to CIN 
would have poor long term survival independent of CIN. A systematic review and meta-analysis looked at patients 
with CIN after a contrast CT compared to patients without contrast CT scans, 25,950 patients were included in this 
analysis and there was no difference in incidence of dialysis or death between the two patient groups [34].  
 Another situation that commonly arises is repeat use of IV contrast within a short period of time. This situation can 
occur if a patient needs both a diagnostic and radiation planning CT scan. A study of 100 consecutive patients 
receiving two administrations of IV contrast within 32 hours did not show any elevation in CIN rates when compared 
to a control group [35]. This small study offers some reassurance of the safety of repeat CT contrast administration if 
medically indicated. 
Treatment and Prevention of CIN 
Multiple methods have been tested to prevent CIN or treat CIN once it has occurred. However, the majority have 
either been negative or not reproduced. A large review [36] of prophylaxis strategies did not find any evidence to 
clearly support any agent to prevent CIN (including hydration). Even so, several authors have concluded that available 
data suggests that hydration either before or after contrast may be beneficial [29, 36]. N-acetylcysteine is the most 
commonly examined pharmacologic agent used to prevent CIN. The available data including multiple meta-analyses 
have not been conclusive [36]. We feel that for patients deemed to be at risk for CIN, extra hydration (oral or IV) 
before and after the contrast is a reasonable approach, even if the evidence for benefit is not conclusive, since there is 
little risk involved.  
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Management of Acute Contrast Reactions 
Acute contrast reactions are an allergic-like reaction to the contrast medium. Most major and minor reactions occur in 
patients without any known risk factor. Virtually all life-threatening reactions occur immediately or within 20 minutes 
of contrast injection. For these reasons, it is recommended that a physician is present within the department whenever 
IV contrast is used. Also, all areas where contrast is given need to be equipped with an emergency anaphylaxis box.  
Most acute contrast reactions occur in people with no known risk factor and occur shortly after the administration of 
the IV contrast; 70% of reactions occur in the first 5 minutes [37]. Thus, diligence is important.  The most benign of 
the acute reactions is hives (urticaria) this is not life-threatening, and generally only patient reassurance is indicated. If 
symptomatic, a single dose of diphenhydramine (Benadryl) can be given orally or intravenously. For more severe 
reactions (edema, bronchospasm, hypotension) supplemental oxygen should be provided for all patients, rapid 
response team should be alerted, and consideration may be given to subcutaneous epinephrine (1:1000, 0.1 to 0.3 ml).  
It should be noted that warmth or flushing, albeit unpleasant, is physiologic and not considered an adverse event and 
not indicative of a future adverse event. Table 3 outlines acute contrast reactions and appropriate treatment.  
 
 
Table 3 Acute Contrast Reactions 
Reaction Action 
Warmth, flushing · No action (patient reassurance only that this is physiologic and not harmful) 
Hives (urticaria)  ·  Discontinue injection.  
· Can consider diphenydramine (Benadryl) 
Edema  · Epinephrine SC 
· Oxygen 
Bronchospasm · Oxygen 
· Beta-agonist (albuteral)  
· Epinephrine if not improved 
Hypotension · Oxygen 
· Elevate legs  
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Table 4 Risk factors for Contrast Allergic Reaction 
Previous reaction to IV contrast 
Severe allergies to food or medicine  
 
In a Japanese nationwide study looking at 337,647 patients the incidence of severe and very severe reactions with low 
osmolar contrast were 0.04% and 0.004% respectively [38]. In several studies looking at risk factors for predicting 
allergic reactions, the most commonly found risk factors include history of previous reaction, and any allergy (drug or 
food) requiring medical treatment [38, 39] (Table 4). Several reports have found asthma to be a risk factor [38-39] but 
other studies have not [40] and it is felt that patients with well controlled asthma are not at risk for reactions [41]. 
While allergy to shellfish is often cited as a contraindication to IV contrast this has been dispelled as a myth (albeit a 
rather well entrenched myth). While shellfish do contain iodine, the iodine in shellfish is not the source of allergy (the 
major allergen is in the shellfish muscle), nor is iodine in contrast the allergic agent (it is the contrast molecule) [42]. 
That being said, allergy to shellfish needs to be regarded in the context of multiple additional allergies which is a 
known contrast reaction risk factor.   
Prevention of Contrast Reactions 
There is some data that the incidence of contrast reactions can be reduced using premedications, but this data is limited 
and their conclusions are controversial [38,43,44]. In a randomized study 1,155 patients were randomized between 32 
mg methylpredisolone 6-24 and 2 hours versus placebo prior to IV contrast and found that the prophylactic measure 
protected against mild contrast reactions (4.9% without prednisone reduced to 1.7%). Secondary to a limited number 
of events it was not possible to conclude that moderate and severe reactions were also reduced [43]. The American 
College of Radiology guidelines for prophylaxis are seen in Table 5 [45]. Although the evidence for prevention of 
serious reactions is not convincing we feel that the prophylaxis regimen is well tolerated with low risk and remains 
recommended for patients at elevated risk for reactions (Table 4).   
 
Table 5 prophylaxis medication in high risk patients (American College of Radiology) 
50 mg prednisone 13 , 7, 1 hours before contrast 
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The use of CT contrast is an important adjunct to obtaining the best possible CT images and thus optimal contouring 
and target definition in radiation oncology. The two issues of concern when using CT contrast are CIN and acute 
contrast reaction. There is a paucity of data regarding CIN on several levels; definition, incidence, patients at risk, 
long-term effects of CIN, and prevention.  CIN is an uncommon event and almost always self-resolving, and by 
using some simple screening and algorithm (Table 2, Figure 2) patients can safely receive CT contrast. Allergic-like 
reactions are rare events, most often seen in patients without any risk factors, but do occur disproportionately in 
patients with history of previous contrast reaction and severe allergies. For these high-risk patients we recommend 
prophylactic medication (Table 5). Most allergic reactions occur in patients without any risk factors and occur shortly 
after contrast administration and thus we recommend that the physician be present in the department whenever CT 
contrast is given.  
 
 
Figure 2 Algorithm for delivering IV contrast 
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